Sneha Mohan

Dr. Sneha Mohan

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 August 2022 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
Maheswaran DhanasekaranMaheswaran Dhanasekaran
Maheswaran Dhanasekaran
SMSneha Mohan
Sneha Mohan
DEDana Erickson
Dana Erickson
PSPankaj Shah
Pankaj Shah
LSLinda M. Szymanski
Linda M. Szymanski
AEAoife Egan
Aoife Egan
Context Diabetic ketoacidosis (DKA) in pregnancy is an obstetric emergency with risk of maternofetal death. Objective This work aimed to evaluate DKA events in pregnant women admitted to our inpatient obstetric service, and to examine associated clinical risk factors, presentation, and pregnancy outcomes. Methods A retrospective cohort study was conducted at the Mayo Clinic, Rochester, Minnesota, USA, and included women aged 17 to 45 years who were treated for DKA during pregnancy between January 1, 2004 and December 31, 2021. Main outcome measures included maternal and fetal death along with a broad spectrum of maternal and fetal pregnancy outcomes. Results A total of 71 DKA events were identified in 58 pregnancies among 51 women, 48 (82.8%) of whom had type 1 diabetes. There were no maternal deaths, but fetal demise occurred in 10 (17.2%) pregnancies (6 miscarriages and 4 stillbirths). Maternal social stressors were frequently present (n = 30, 51.0%), and glycemic control was suboptimal (median first trimester glycated hemoglobin A1c = 9.0%). Preeclampsia was diagnosed in 17 (29.3%) pregnancies. Infants born to women with DKA were large for gestational age (n = 16, 33.3%), suffered from neonatal hypoglycemia (n = 29, 60.4%) and required intensive care unit admission (n = 25, 52.1%). Conclusion DKA is associated with a high rate of maternofetal morbidity and fetal loss. Prenatal education strategies for women with diabetes mellitus should include a strong focus on DKA prevention, and clinicians and patients should have a high index of suspicion for DKA in all pregnant women who present with symptoms that could be attributed to this condition.

3 January 2025 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
SMSneha Mohan
Sneha Mohan
HCHannah E Christie
Hannah E Christie
MLMarcello C Laurenti
Marcello C Laurenti
AEAoife Egan
Aoife Egan
KBKent R Bailey
Kent R Bailey
AVAdrian Vella
Adrian Vella
Context: Defects in insulin secretion and action contribute to the progression of prediabetes to diabetes. However, the contribution of α-cell dysfunction to this process has been unclear. Objective: This work aimed to understand the relative contributions of α-cell and β-cell dysfunction to declining glucose tolerance. Methods: A longitudinal, community-based observational study was conducted at a clinical research unit at an academic medical center. We studied 96 individuals without diabetes (age 55 ± 1 years; body mass index 27.7 ± 0.4) on 2 occasions, 3 years apart using an oral 75-g glucose challenge. Indices for insulin secretion and action were estimated using the oral minimal model. Glucagon secretion rate (GSR) was estimated by deconvolution from peripheral glucagon concentrations. Main outcome measures included glucose tolerance status (categorical variable) and then symmetrical percentage change in peak and 120-minute glucose (post oral glucose tolerance test) concentrations (continuous variables). Results: A total of 32 individuals progressed from normal to impaired glucose tolerance (IGT) or from IGT to type 2 diabetes. The disposition index (DI) declined in the progressors (568 ± 98 vs 403 ± 65 10−4 dL/kg/min per μU/mL, baseline vs 3 years; P = .04). α-Cell suppression by glucose (δGSR/δglucose) did not change in the nonprogressors (1.5 ± 0.1 vs 1.3 ± 0.1 nmol/min/L; P = .37) but decreased (1.0 ± 0.2 vs 0.8 ± 0.2 nmol/min/L; P < .01) in those who progressed. Analysis of the entire cohort showed that DI and δGSR/δglucose were independently and inversely correlated with an increase in glycemic excursion. Conclusion: These data show that α-cell dysfunction accompanies a decline in β-cell function as IGT or overt type 2 diabetes develops.

26 June 2023 in Thyroid®
Verified
Journal Article
Closed access
FTFreddy Toloza
Freddy Toloza
OKOmar El Kawkgi
Omar El Kawkgi
HSHorace Spencer
Horace Spencer
SMSherin Elsa Mathews
Sherin Elsa Mathews
AGAndrea Garcia
Andrea Garcia
SMSpyridoula Maraka
Spyridoula Maraka
Background: The frequency and factors associated with thyroid hormone replacement therapy among patients with subclinical hypothyroidism remains uncertain. Methods: In this electronic health records-based observational cohort study, we included adults diagnosed with subclinical hypothyroidism from four academic centers (United States of America and Mexico) from 01/01/2016 to 12/31/2018). We aimed to identify the determinants of thyroid hormone replacement therapy for subclinical hypothyroidism and the frequency of treated subclinical hypothyroidism. Results: A total of 796 patients (65.2% women) had subclinical hypothyroidism, and 165 (20.7%) were treated with thyroid hormone replacement therapy. The treated group was younger [51.0 (SD 18.3) vs. 55.3 (SD 18.2) years, P= .008] and had a higher proportion of women (72.7% vs. 63.2%, P= .03) compared to the untreated group. Only 46.7% of patients in the treated group and 65.6% in the untreated group had confirmatory thyroid function tests before the decision to start thyroid hormone replacement therapy was made. There was no difference in the frequency of thyroid autoimmunity evaluation, but a positive thyroid autoimmunity test was more frequent in the treated group compared to the untreated group (48.2% vs. 20.3%, P= <.001). In a multivariable logistic regression model, female sex (OR=1.71, 95% CI 1.13 to 2.59, P= .01) and index thyrotropin level (OR=1.97, 95% CI 1.56 to 2.49, P= <.001 for every SD (2.75 mIU/L) change) were associated with higher odds of treatment. Conclusions: Among patients with subclinical hypothyroidism, female sex, and index thyrotropin level were associated with higher odds of treatment. Moreover, in our population, the decision to treat or not to treat subclinical hypothyroidism was often based on only one set of abnormal thyroid function tests, and thyroid autoimmunity assessment was underused.

23 December 2025 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
HCHannah E. Christie
Hannah E. Christie
SMSneha Mohan
Sneha Mohan
AEAoife Egan
Aoife Egan
FBFederica Boscolo
Federica Boscolo
CMChiara Dalla Man
Chiara Dalla Man
AVAdrian Vella
Adrian Vella
BACKGROUND. Amino acid (AA) concentrations are increased in prediabetes and diabetes. Since AA stimulate glucagon secretion which should then increase hepatic AA catabolism, it has been hypothesized that hepatic resistance (associated with hepatic fat content) to glucagon’s actions on AA metabolism leads to hyperglucagonemia and hyperglycemia. METHODS. To test this hypothesis, we therefore studied lean and obese individuals, the latter group with and without hepatic steatosis as defined by Proton Density Fat Fraction (PDFF) > 5%. After an overnight fast, femoral vein, femoral artery, and hepatic vein catheters were placed. [3-3H] glucose and L-[1-13C,15N]-leucine were used to measure glucose turnover and leucine oxidation respectively. During a hyperglycemic clamp, an amino acid mixture was infused together with insulin and glucagon (1.5 ng/kg/min 0 – 120 min; 3.0 ng/kg/min 120 – 240 min). Tracer-based measurement of hepatic leucine oxidation in response to rising glucagon concentrations and splanchnic balance (measured using arterio-venous differences across the liver), of the other AA were the main outcomes measured. RESULTS. The presence of hepatic steatosis did not alter hepatic glucose metabolism and leucine oxidation in response to insulin and rising concentrations of glucagon. Splanchnic balance of a few amino acids, and related metabolites differed amongst the groups. However, across-group differences of AA splanchnic balance in response to glucagon were unaffected by the presence of hepatic steatosis. CONCLUSION. The action of glucagon on hepatic amino acid metabolism is unaffected by hepatic steatosis in humans. TRIAL REGISTRATION. This study was registered at Clinical Trials.Gov: NCT05500586. FUNDING. This work was funding by the NIH.

23 February 2024 in JCEM Case Reports
Verified
Journal Article
Open access
PDF file
SMSneha Mohan
Sneha Mohan
MSMichael Sheehan
Michael Sheehan
PTPeter Tebben
Peter Tebben
RWRobert Wermers
Robert Wermers
Elevated 1,25-dihydroxyvitamin D (1,25(OH)2D) is a rare cause of non–parathyroid hormone (PTH)–mediated hypercalcemia seen in granulomatous disease, malignancy (most often lymphoma), or genetic mutations. Therapeutic options are limited. We report the case of a 67-year-old White man with nonmalignant, nongranulomatous, 1,25(OH)2D-mediated hypercalcemia treated successfully with cinacalcet. At presentation, he had hypercalcemia, hypercalciuria with recurrent nephrolithiasis, low PTH, elevated 1,25(OH)2D, and normal 25-hydroxyvitamin D. The 1,25(OH)2D levels were inappropriate in the setting of hypercalcemia with low PTH. Evaluations for sarcoidosis, tuberculosis, and malignancy were negative. Genetic testing showed biallelic variants in the CYP24A1 gene. Cinacalcet was trialed and showed normalization of calcium levels. On cinacalcet, biochemical indices showed a slight increase in 1,25(OH)2D and 24-hour urine calcium and mild decrease in PTH. He briefly experienced symptomatic hypocalcemia that resolved after reducing cinacalcet dose. Due to limited symptomatic benefit, he opted to stop cinacalcet. Additional follow-up showed intermittently elevated serum calcium levels after stopping cinacalcet, most recently 10.3 mg/dL. Cinacalcet may be a therapeutic option in nonmalignant, 1,25(OH)2D-mediated hypercalcemia. Further study is necessary to confirm efficacy, understand risks and benefits, and elucidate mechanism(s) of action.

28 December 2024 in Journal of Vascular and Interventional Radiology
Verified
Journal Article
Closed access
SMSneha Mohan
Sneha Mohan
OSOmair A. Shariq
Omair A. Shariq
JAJames C. Andrews
James C. Andrews
WYWilliam F. Young
William F. Young